Strategy
CAB is a screening tool for investigating the surface interfacial properties of secondary processed micronized APIs and their influence on blending dynamics, stability and in vitro performance. CAB directly quantifies the relative magnitudes of the cohesive and adhesive forces that govern formulation structure and ultimately product functionality.
Development
CAB can be utilised throughout all phases of pharmaceutical drug product development. These include API process development, early phase formulation development and troubleshooting during scale-up and routine testing of batch-to-batch variability.
Delivery
CAB has been successfully utilised as a screening tool to determine the influence of specific API-excipient combinations on formulation structure, direct characterisation of API variability and the influence of processing and storage conditions on the interfacial properties of micronised APIs.
